Sympathetic skin response for early detection of type 2 diabetic peripheral neuropathy and nephropathy.
Diabetic nephropathy
Diabetic peripheral neuropathy
Microalbuminuria
Nerve conduction studies
Sympathetic skin response
Journal
Journal of diabetes investigation
ISSN: 2040-1124
Titre abrégé: J Diabetes Investig
Pays: Japan
ID NLM: 101520702
Informations de publication
Date de publication:
04 Oct 2023
04 Oct 2023
Historique:
revised:
16
08
2023
received:
27
03
2023
accepted:
29
08
2023
medline:
5
10
2023
pubmed:
5
10
2023
entrez:
5
10
2023
Statut:
aheadofprint
Résumé
Diabetic peripheral neuropathy (DPN) and diabetic nephropathy (DN) are common complications of type 2 diabetes mellitus (T2DM). Although nerve conduction studies (NCS) and sympathetic skin response (SSR) can detect DPN, the more sensitive method for early diagnosis remains unclear. Furthermore, whether DPN can be used as a predictor for diabetic nephropathy needs clarification. We evaluated nerve conduction studies, sympathetic skin response, and the diabetic nephropathy indicator microalbuminuria (MAU) in 192 patients with type 2 diabetes mellitus and 50 healthy controls. Patients with type 2 diabetes mellitus showed a lower sensory nerve conduction velocity (SCV), sensory active nerve potential (SNAP), motor nerve conduction velocity (MCV), and compound motor action potential (CMAP) than the controls on NCS. Abnormal rates for nerve conduction studies and sympathetic skin response were 75.0% and 83.3%, respectively, in patients with type 2 diabetes mellitus. Interestingly, 54.2% of patients with normal nerve conduction studies had an abnormal sympathetic skin response. Moreover, we found a positive correlation between sympathetic skin response and microalbuminuria for the first time. The abnormal rate of microalbuminuria was 53.8%, lower than that of abnormal nerve conduction studies or sympathetic skin response patients. Sympathetic skin response is a more sensitive method than nerve conduction studies for the early diagnosis of diabetic peripheral neuropathy. Abnormal sympathetic skin response might serve as an indicator for early diabetic nephropathy. Additionally, diabetic peripheral neuropathy may occur earlier than diabetic nephropathy in the development of type 2 diabetes mellitus.
Sections du résumé
BACKGROUND
BACKGROUND
Diabetic peripheral neuropathy (DPN) and diabetic nephropathy (DN) are common complications of type 2 diabetes mellitus (T2DM). Although nerve conduction studies (NCS) and sympathetic skin response (SSR) can detect DPN, the more sensitive method for early diagnosis remains unclear. Furthermore, whether DPN can be used as a predictor for diabetic nephropathy needs clarification.
METHODS
METHODS
We evaluated nerve conduction studies, sympathetic skin response, and the diabetic nephropathy indicator microalbuminuria (MAU) in 192 patients with type 2 diabetes mellitus and 50 healthy controls.
RESULTS
RESULTS
Patients with type 2 diabetes mellitus showed a lower sensory nerve conduction velocity (SCV), sensory active nerve potential (SNAP), motor nerve conduction velocity (MCV), and compound motor action potential (CMAP) than the controls on NCS. Abnormal rates for nerve conduction studies and sympathetic skin response were 75.0% and 83.3%, respectively, in patients with type 2 diabetes mellitus. Interestingly, 54.2% of patients with normal nerve conduction studies had an abnormal sympathetic skin response. Moreover, we found a positive correlation between sympathetic skin response and microalbuminuria for the first time. The abnormal rate of microalbuminuria was 53.8%, lower than that of abnormal nerve conduction studies or sympathetic skin response patients.
CONCLUSION
CONCLUSIONS
Sympathetic skin response is a more sensitive method than nerve conduction studies for the early diagnosis of diabetic peripheral neuropathy. Abnormal sympathetic skin response might serve as an indicator for early diabetic nephropathy. Additionally, diabetic peripheral neuropathy may occur earlier than diabetic nephropathy in the development of type 2 diabetes mellitus.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Guangzhou Science, Technology and Innovation Commission
ID : 201704020043
Organisme : National Natural Science Foundation of China
ID : 81701240
Organisme : Natural Science Foundation of Guangdong Province
ID : 2016A030310283
Informations de copyright
© 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
Références
Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138: 271-281.
Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care 2004; 27: 1591-1597.
Feldman EL, Nave KA, Jensen TS, et al. New horizons in diabetic neuropathy: Mechanisms, bioenergetics, and pain. Neuron 2017; 93: 1296-1313.
Barrell K, Smith AG. Peripheral neuropathy. Med Clin North Am 2019; 103: 383-397.
Ward RE, Caserotti P, Cauley JA, et al. Mobility-related consequences of reduced lower-extremity peripheral nerve function with age: A systematic review. Aging Dis 2016; 7: 466-478.
London ZN, Mundwiler A, Oral H, et al. Nerve conduction studies are safe in patients with central venous catheters. Muscle Nerve 2017; 56: 321-323.
Tavee J. Nerve conduction studies: Basic concepts. Handb Clin Neurol 2019; 160: 217-224.
Kiziltan ME, Gunduz A, Kiziltan G, et al. Peripheral neuropathy in patients with diabetic foot ulcers: Clinical and nerve conduction study. J Neurol Sci 2007; 258: 75-79.
Braddom RL, Hollis JB, Castell DO. Diabetic peripheral neuropathy: A correlation of nerve conduction studies and clinical findings. Arch Phys Med Rehabil 1977; 58: 308-313.
Niakan E, Harati Y. Sympathetic skin response in diabetic peripheral neuropathy. Muscle Nerve 1988; 11: 261-264.
Al-Moallem MA, Zaidan RM, Alkali NH. The sympathetic skin response in diabetic neuropathy and its relationship to autonomic symptoms. Saudi Med J 2008; 29: 568-572.
Robles NR, Solis M, Albarran L, et al. Sympathetic skin response in hemodialysis patients: Correlation with nerve conduction studies and adequacy of dialysis. Nephron 1999; 82: 12-16.
Nazhel B, Yetkin I, Irkec C, et al. Sympathetic skin response in diabetic neuropathy. Electromyogr Clin Neurophysiol 2002; 42: 181-185.
Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol 2016; 12: 357-370.
Flyvbjerg A. The role of the complement system in diabetic nephropathy. Nat Rev Nephrol 2017; 13: 311-318.
Zhang XX, Kong J, Yun K. Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China: A meta-analysis of observational studies. J Diabetes Res 2020; 2020: 2315607.
Thipsawat S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature. Diab Vasc Dis Res 2021; 18: 14791641211058856.
Papatheodorou K, Papanas N, Banach M, et al. Complications of diabetes 2016. J Diabetes Res 2016; 2016: 6989453.
Hur J, O'Brien PD, Nair V, et al. Transcriptional networks of murine diabetic peripheral neuropathy and nephropathy: Common and distinct gene expression patterns. Diabetologia 2016; 59: 1297-1306.
Dyck PJ, Davies JL, Wilson DM, et al. Risk factors for severity of diabetic polyneuropathy: Intensive longitudinal assessment of the Rochester diabetic neuropathy study cohort. Diabetes Care 1999; 22: 1479-1486.
Roikjer J, Morch CD, Ejskjaer N. Diabetic peripheral neuropathy: Diagnosis and treatment. Curr Drug Saf 2021; 16: 2-16.
De Silva L, Weir MR. Renin inhibition and microalbuminuria development: Meaningful predictor of kidney disease progression. Curr Opin Nephrol Hypertens 2010; 19: 437-443.
Thakur V, Chattopadhyay M. Early urinary markers for diabetic and other kidney diseases. Curr Drug Targets 2018; 19: 825-831.
Papadopoulou-Marketou N, Kanaka-Gantenbein C, Marketos N, et al. Biomarkers of diabetic nephropathy: A 2017 update. Crit Rev Clin Lab Sci 2017; 54: 326-342.
Van JA, Scholey JW, Konvalinka A. Insights into diabetic kidney disease using urinary proteomics and bioinformatics. J Am Soc Nephrol 2017; 28: 1050-1061.
Javed S, Hayat T, Menon L, et al. Diabetic peripheral neuropathy in people with type 2 diabetes: Too little too late. Diabetic Med 2019; 37: 573-579.
Wang F, Zhang J, Yu J, et al. Diagnostic accuracy of monofilament tests for detecting diabetic peripheral neuropathy: A systematic review and meta-analysis. J Diabetes Res 2017; 2017: 8787261.
Brown JJ, Pribesh SL, Baskette KG, et al. A comparison of screening tools for the early detection of peripheral neuropathy in adults with and without type 2 diabetes. J Diabetes Res 2017; 2017: 1467213.
Vinik AI, Bril V, Litchy WJ, et al. Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy. Muscle Nerve 2005; 32: 619-625.
Morimoto J, Suzuki Y, Tada A, et al. Time-course changes in nerve conduction velocity (NCV) in type 2 diabetes. J Diabetes Complications 2012; 26: 237-240.
Kushnir M, Klein C, Kimiagar Y, et al. Medial dorsal superficial peroneal nerve studies in patients with polyneuropathy and normal sural responses. Muscle Nerve 2005; 31: 386-389.
Lo YL, Xu LQ, Leoh TH, et al. Superficial peroneal sensory and sural nerve conduction studies in peripheral neuropathy. J Clin Neurosci 2006; 13: 547-549.
Sylantiev C, Schwartz R, Chapman J, et al. Medial plantar nerve testing facilitates identification of polyneuropathy. Muscle Nerve 2008; 38: 1595-1598.
Sanada LS, Tavares MR, Sato KL, et al. Association of chronic diabetes and hypertension in sural nerve morphometry: An experimental study. Diabetol Metab Syndr 2015; 7: 9.
Semprini R, Martorana A, Ragonese M, et al. Observational clinical and nerve conduction study on effects of a nutraceutical combination on painful diabetic distal symmetric sensory-motor neuropathy in patients with diabetes type 1 and type 2. Minerva Med 2018; 109: 358-362.
Kakrani AL, Gokhale VS, Vohra KV, et al. Clinical and nerve conduction study correlation in patients of diabetic neuropathy. J Assoc Physicians India 2014; 62: 24-27.
Huang YN, Jia ZR, Shi X, et al. Value of sympathetic skin response test in the early diagnosis of diabetic neuropathy. Chin Med J (Engl) 2004; 117: 1317-1320.
Braune HJ, Horter C. Sympathetic skin response in diabetic neuropathy: A prospective clinical and neurophysiological trial on 100 patients. J Neurol Sci 1996; 138: 120-124.
Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes: A review of early natural history, pathogenesis, and diagnosis. Diabetes Metab Res Rev 2017; 33: e2841.
Papadopoulou-Marketou N, Paschou SA, Marketos N, et al. Diabetic nephropathy in type 1 diabetes. Minerva Med 2018; 109: 218-228.
Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester diabetic neuropathy study. Neurology 1993; 43: 817-824.
Xue-lian Z, Wei W, Ren-bin W, et al. Clinical association analysis between diabetic peripheral neuropathy and diabetic nephropathy. Chinese J Med 2018; 06: 606-609.
Charles M, Soedamah-Muthu SS, Tesfaye S, et al. Low peripheral nerve conduction velocities and amplitudes are strongly related to diabetic microvascular complications in type 1 diabetes: The EURODIAB prospective complications study. Diabetes Care 2010; 33: 2648-2653.